Dusa pharmaceuticals inc (DUSA)
CashFlow / Yearly
Dec'11Dec'10Dec'09
Net income

7,319

2,702

-2,508

Less: income from discontinued operations

-526

-139

-250

Net income from continuing operations

6,793

2,563

-2,758

Accretion of premiums and discounts on marketable securities

13

-2

-46

Realized loss on sales of marketable securities

-

-

-43

Share-based compensation

1,207

1,107

800

Depreciation and amortization

445

393

455

Loss on change in fair value of warrants

-1,013

-390

-376

Deferred revenues recognized

1,728

1,179

960

Accounts receivable

504

735

327

Inventory

775

-20

-432

Prepaid and other assets

26

-217

-404

Accounts payable

642

-464

335

Accrued compensation and other accrued expenses

599

1,154

-871

Other liabilities

-23

-41

-121

NET CASH PROVIDED BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS

7,629

3,430

-2,145

NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES FROM DISCONTINUED OPERATIONS

409

-106

362

NET CASH PROVIDED BY OPERATING ACTIVITIES

8,039

3,324

-1,782

Purchases of marketable securities

4,497

12,742

12,049

Proceeds from maturities and sales of marketable securities

11,430

10,885

17,748

Restricted cash

1

0

0

Purchases of property, plant and equipment

463

215

178

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS

6,467

-2,073

5,519

NET CASH PROVIDED BY INVESTING ACTIVITIES FROM DISCONTINUED OPERATIONS

750

-

-

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

7,217

-2,073

5,519

Stock option exercises

516

62

-

Settlements of restricted stock for tax withholding obligations

233

42

4

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

282

20

-4

NET INCREASE IN CASH AND CASH EQUIVALENTS

15,539

1,271

3,732

Less (increase) decrease in cash and cash equivalents from discontinued operations

-1,159

106

-362

Increase in cash and cash equivalents from continuing operations

14,379

1,377

3,370